Stable silencing of the inactive X chromosome (Xi) in female mammals is crucial for the development of embryos and their postnatal health. SmcHD1 is essential for stable silencing of the Xi, and its functional deficiency results in derepression of many X-inactivated genes. Although SmcHD1 has been suggested to play an important role in the formation of higher-order chromatin structure of the Xi, the underlying mechanism is largely unknown. Here, we explore the epigenetic state of the Xi in SmcHD1-deficient epiblast stem cells and mouse embryonic fibroblasts in comparison with their wild-type counterparts. The results suggest that SmcHD1 underlies the formation of H3K9me3-enriched blocks on the Xi, which, although the importance of H3K9me3 has been largely overlooked in mice, play a crucial role in the establishment of the stably silenced state. We propose that the H3K9me3 blocks formed on the Xi facilitate robust heterochromatin formation in combination with H3K27me3, and that the substantial loss of H3K9me3 caused by SmcHD1 deficiency leads to aberrant distribution of H3K27me3 on the Xi and derepression of X-inactivated genes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1242/dev.200864 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of a pathogenic SMCHD1 variant in a Chinese patient with bosma arhinia microphthalmia syndrome: a case report.
BMC Med Genomics
May 2024
Department of Cardiovascular Surgery, the Second Xiangya Hospital of Central South University, Changsha, China.
Background: Bosma arhinia microphthalmia syndrome (BAMS; MIM603457) is a rare genetic disorder, predominantly autosomal dominant. It is a multi-system developmental disorder characterized by severe hypoplasia of the nose and eyes, and reproductive system defects. BAMS is extremely rare in the world and no cases have been reported in Chinese population so far.
View Article and Find Full Text PDFNasal Construction in Congenital Arhinia Due to Novel SMCHD1 Gene Variant.
J Craniofac Surg
May 2023
Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Harvard Medical School.
Arhinia, or congenital absence of the nose, is an exceedingly rare anomaly caused by pathogenic variants in the gene SMCHD1 . Arhinia exhibits unique reconstructive challenges, as the midface is deficient in skeletal and soft tissue structures. The authors present 2 related patients with arhinia who harbor a novel SMCHD1 gene variant and illustrate their surgical midface and nasal construction.
View Article and Find Full Text PDFSmcHD1 underlies the formation of H3K9me3 blocks on the inactive X chromosome in mice.
Development
August 2022
Department of Advanced Bioscience, Graduate School of Agriculture, Kindai University, Nara 631-8505, Japan.
Stable silencing of the inactive X chromosome (Xi) in female mammals is crucial for the development of embryos and their postnatal health. SmcHD1 is essential for stable silencing of the Xi, and its functional deficiency results in derepression of many X-inactivated genes. Although SmcHD1 has been suggested to play an important role in the formation of higher-order chromatin structure of the Xi, the underlying mechanism is largely unknown.
View Article and Find Full Text PDFCross-sectional Neuromuscular Phenotyping Study of Patients With Arhinia With Variants.
Neurology
March 2022
From the Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch (P.M., Y.H., S.D., D.S., A.R.F., C.G.B.), and International Neuroinfectious Diseases Unit, Division of Neuroimmunology and Neurovirology (B.J.B.), National Institute of Neurological Disorders and Stroke, National Institute of Child Health and Development (A.D., B.M.), and Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (R.V.), National Institutes of Health, Bethesda, MD; Department of Pharmacology (N.C., P.L.J., T.J.), Reno School of Medicine, University of Nevada; Pediatric Neuroendocrinology Group, Clinical Research Branch, National Institute of Environmental Health Sciences (K.I., N.D.S.), National Institutes of Health, Research Triangle Park, NC; Department of Neurosciences (C.G.K.), University of California, San Diego; Department of Pediatric Neurology, Center for Chronically Sick Children and Institute of Cell Biology and Neurobiology (A.M.K.), Charitè-Universitätsmedizin Berlin, Germany; Institute for Diagnostic and Interventional Radiology (C.-H.C.), University Clinic, Jena, Germany; Division of Pediatric Genetics, Department of Pediatrics (B.R.), University of California, Los Angeles; Nashville Skin and Cancer (A.R.), TN; Florida Dermatology and Skin Cancer Centers (K.W.F.), Winter Haven; and Department of Pathology, University of Iowa Carver College of Medicine (S.A.M.), Iowa City.
Background And Objectives: Facioscapulohumeral muscular dystrophy type 2 (FSHD2) and arhinia are 2 distinct disorders caused by pathogenic variants in the same gene: . The mechanism underlying this phenotypic divergence remains unclear. In this study, we characterize the neuromuscular phenotype of individuals with arhinia caused by variants and analyze their complex genetic and epigenetic criteria to assess their risk for FSHD2.
View Article and Find Full Text PDFFacioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
Neuromuscul Disord
November 2021
Department of Neurology, Concord Repatriation General Hospital, Concord, New South Wales 2139, Australia; Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia; Molecular Medicine Laboratory, Concord Repatriation General Hospital, Concord, New South Wales 2139, Australia; Sydney Medical School, University of Sydney, Camperdown, New South Wales 2050, Australia. Electronic address:
Facioscapulohumeral muscular dystrophy (FSHD) is a common genetic disease of the skeletal muscle with a characteristic pattern of weakness. Facioscapulohumeral muscular dystrophy type 2 (FSHD2) accounts for approximately 5% of all cases of FSHD and describes patients without a D4Z4 repeat contraction on chromosome 4. Phenotypically FSHD2 shows virtually no difference from FSHD1 and both forms of FSHD arise via a common downstream mechanism of epigenetic derepression of the transcription factor DUX4 in skeletal muscle cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!